Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
Bugando Medical Centre, Mwanza, United Republic of Tanzania.
BMJ Open. 2021 Dec 31;11(12):e049979. doi: 10.1136/bmjopen-2021-049979.
The paucity of data describing cardiovascular disease (CVD) in pregnancy in many parts of Africa including Tanzania has given rise to challenges in proper management by the healthcare providers. This study is set out to (1) determine the prevalence of a range of CVDs during pregnancy in women attending antenatal clinics in Tanzania and (2) determine the impact of these CVDs on maternal and fetal outcomes at delivery.
This is a cross-sectional study with a prospective component to be conducted in two referral hospitals in Tanzania. Pregnant women aged ≥18 years diagnosed with a CVD during the antenatal period are being identified and extensively characterised by performing clinical assessment, modified WHO staging, electrocardiography, echocardiography and laboratory tests. Patients identified with CVDs (exposed) and a subset without (unexposed) will be followed up to determine maternal and fetal outcomes at delivery. A minimum sample of 1560 will be sufficient to estimate the prevalence of CVDs with a 95% CI of 2.75% to 5.25%.
The study is being conducted in accordance with the Helsinki declaration on studies involving human subjects. Ethical approvals have been obtained from Muhimbili University (reference number DA.282/298/01.C/) and Bugando Medical Centre (reference number CREC/330/2019) Ethics Committees. Informed consent is sought from all potential participants before any interview or investigations are performed. Study findings will be disseminated to the scientific community through different methods. Results will also be communicated to policymakers and to the public, as appropriate.
在包括坦桑尼亚在内的许多非洲地区,关于妊娠期间心血管疾病(CVD)的数据很少,这给医疗保健提供者的妥善管理带来了挑战。本研究旨在:(1) 确定在坦桑尼亚产前诊所就诊的妇女中一系列 CVD 的流行情况,(2) 确定这些 CVD 对分娩时母婴结局的影响。
这是一项在坦桑尼亚的两家转诊医院进行的横断面研究,具有前瞻性部分。在产前期间被诊断患有 CVD 的年龄≥18 岁的孕妇正在被识别,并通过进行临床评估、WHO 改良分期、心电图、超声心动图和实验室检查进行广泛的特征描述。确定患有 CVD(暴露组)和未患有 CVD(未暴露组)的患者将进行随访,以确定分娩时的母婴结局。一个最小样本量为 1560 将足以估计 CVD 的患病率,95%置信区间为 2.75%至 5.25%。
本研究是按照涉及人类受试者的赫尔辛基宣言进行的。已获得穆希比利大学(参考编号 DA.282/298/01.C/)和布甘达医学中心(参考编号 CREC/330/2019)伦理委员会的批准。在进行任何访谈或调查之前,都要向所有潜在参与者征求知情同意。研究结果将通过不同的方法向科学界传播。还将根据需要向政策制定者和公众传达研究结果。